Fig. 1From: Emerging therapeutic strategies for unmet need in neovascular age-related macular degenerationVEGF ligands and receptors. The VEGF ligand family (comprising VEGF-A, VEGF-B, VEGF-C, VEGF-D, virally encoded VEGF-E and placental growth factor (PlGF)) interacts selectively with 3 cell surface receptors (VEGFR1, VEGFR2, VEGFR3). Currently approved therapies are indicated in black font. Examples of emerging or experimental therapies are shown in blue font. Refer to text for detailBack to article page